GlaxoSmithKline data shows Coreg CR reduces blood pressure

By Elaine Rigoli

Tampa, Fla., May 17 - GlaxoSmithKline's Coreg CR reduced blood pressure over a full 24-hour dosing interval, according to data presented at the American Society for Hypertension 21st annual scientific meeting and exposition in New York.

Additionally, the data show that Coreg CR was well-tolerated with no significant difference in incidence of adverse events among patients taking Coreg CR as compared to those taking the placebo.

The data is based on a double-blind, randomized, placebo-controlled, parallel group, multi-center study. Patients were randomized to receive once-daily doses of Coreg CR 20 mg, 40 mg, 80 mg or a placebo for six weeks.

Participants entered the study with a mean 12-hour daytime diastolic blood pressure by ambulatory blood pressure monitoring of greater than or equal to 90 mmHg, but less than or equal to 109 mmHg, the company said in a news release.

Coreg CR significantly reduced systolic blood pressure by 6.8 mmHg, 10.1 mmHg and 12.5 mmHg in the Coreg CR 20, 40 and 80 mg treatment groups, respectively, the release said.

The effects on blood pressure of Coreg CR were evaluated using 24-hour ambulatory blood-pressure monitoring.

Based in London, GlaxoSmithKline is a research-based pharmaceutical and health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.